Expert Ratings For Blueprint Medicines

During the last three months, 17 analysts shared their evaluations of Blueprint Medicines (NASDAQ:BPMC), revealing diverse outlooks from bullish to bearish.Summarizing their recent assessments, the ta

BenzingaJun 28 21:00

Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $130

Needham analyst Ami Fadia maintains $Blueprint Medicines(BPMC.US)$ with a buy rating, and maintains the target price at $130.According to TipRanks data, the analyst has a success rate of 43.9% and a t

Futu NewsJun 28 18:33 · Ratings

Blueprint Medicines Price Target Maintained With a $130.00/Share by Needham

Blueprint Medicines Price Target Maintained With a $130.00/Share by Needham

Dow JonesJun 28 18:24

Needham Reiterates Buy on Blueprint Medicines, Maintains $130 Price Target

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $130 price target.

BenzingaJun 28 18:15

Blueprint Medicines(BPMC.US) Officer Sells US$7.71 Million in Common Stock

$Blueprint Medicines(BPMC.US)$ Officer Durso-Bumpus Debra sold 74,034 shares of common stock on Jun 21, 2024 at an average price of $104.19 for a total value of $7.71 million.Source: Announcement What

Futu NewsJun 26 04:39

Blueprint Medicines Insider Sold Shares Worth $7,713,537, According to a Recent SEC Filing

Debra Durso-Bumpus, Chief People Officer, on June 21, 2024, sold 74,034 shares in Blueprint Medicines (BPMC) for $7,713,537. Following the Form 4 filing with the SEC, Durso-Bumpus has control over a t

MT NewswiresJun 26 04:13